Affinium Pharmaceuticals

Skip to content

Main Navigation:

TARGETED ANTIBIOTICS FOR SERIOUS INFECTIONS

Affinium is a specialty pharmaceutical company developing a novel class of antibiotics that target the bacterial fatty acid synthesis pathway. AFN-1252, our lead clinical compound, is a highly-potent, small molecule antibiotic for both oral and IV treatment of staphylococcal infections, including MRSA and all other drug-resistant strains.

FEBRUARY 1, 2012

Affinium Pharmaceuticals, Ltd., Announces First Patient Dosed with Oral AFN-1252 in a Phase 2 Clinical Trial for Acute Bacterial Skin & Skin Structure Infections Click for PDF version (PDF 29KB)

AUGUST 29, 2011

Affinium Pharmaceuticals Announces the Closing of $15 Million Financing Click for PDF version (PDF 158KB)

MAY 2, 2011

Affinium Pharmaceuticals, Ltd., Announces Results of AFN-1252 Multiple Ascending Dose Phase I Clinical Trial Click for PDF version (PDF 28KB)

MARCH 15, 2011

Affinium Pharmaceuticals, Ltd. to Present at Superbugs and Superdrugs Conference in London, UK Click for PDF version (PDF 26KB)

Tab1
Tab2
Tab3
Tab4

You can meet us at:

14th Annual Superbugs & Superdrugs, March 5-6, London, UK
Bio-Europe Spring 2012, March 19-21, Amsterdam, The Netherlands
22nd ECCMID, March 31 – April 3, London, UK
Bio-International 2012, June 18-21, Boston, MA